The company expects the impacts on operations to be minimal but will monitor the situation closely.
In the meantime, the company continues operating to plan and key projects are progressing as scheduled.
The company is continuing to manufacture product for LeMaitre Vascular Inc (FRA:LHU).
LeMaitre’s feedback on its CardioCel® and VascuCel® patch sales remains positive with no downturn in customer orders at this stage.
Notably, the first-in-human 15 patient trial of the company’s ADAPT® single-piece 3D aortic valve for surgical aortic valve replacement at the Universities’ Hospital, Leuven (Belgium) remains on track to proceed as scheduled with the first patient expected to undergo surgery by month’s end.
However, disruption due to COVID-19 demands on hospital resources may delay this into April 2020.
Some disruptions expected
The chief disruption to date is to corporate and medical conferences due to event cancellations and travel restrictions.
The company’s advisory board of physicians continues to meet and will hold its next meeting via video conference next week.
Key additional measures have implemented as part of the company’s coronavirus mitigation strategy and effect:
- travel policy,
- personnel practices, and
- manufacturing continuity.
Excluding manufacturing and research and development, staff and contractors will work from home during the pandemic.